Nectin Therapeutics
A Startup dedicated to the development of next generation immuno-oncology antibodies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $10.0m | Early VC | |
| Total Funding | 000k | ||
Related Content
Nectin Therapeutics is a biotechnology company dedicated to revolutionizing cancer treatment through advanced immunotherapy. The company focuses on harnessing the immune system's power to combat cancer by developing next-generation immuno-oncology (IO) therapies. Unlike existing immunotherapy drugs, which often fail to work for many patients or lose effectiveness over time, Nectin aims to overcome these limitations.
Nectin's primary clients are cancer patients who have not responded to current immunotherapy treatments or have developed resistance. The company operates in the biotech and pharmaceutical market, specifically within the niche of cancer immunotherapy. Nectin's business model revolves around research and development (R&D) of innovative therapeutic candidates, which are then tested in preclinical and clinical trials. The company generates revenue through partnerships, licensing agreements, and eventually, the commercialization of successful therapies.
One of Nectin's leading developments is a monoclonal antibody (mAb) targeting CD112R (PVRIG), an immune inhibitory receptor. Their candidate, NTX2R13, has shown promising therapeutic potential with a clean safety profile in non-human primates (NHP). Additionally, NTX1088 and NTX2R13 have demonstrated significant synergy with each other and with approved PDL1 blockers in preclinical studies. This opens the door for potential combination therapies that could offer more effective treatment options for cancer patients.
Nectin's team comprises experienced professionals, including Chief Scientific Officer Keren Paz, Ph.D., Chief Development Officer Eric Rowinsky, MD, and Acting Chief Medical Officer Guy Cinamon, Ph.D. The company is also supported by a robust Board of Directors and a Scientific Advisory Board, ensuring that their approach is grounded in the best scientific and clinical practices.
In summary, Nectin Therapeutics is at the forefront of developing innovative cancer treatments by addressing the shortcomings of current immunotherapies. Their focus on overcoming tumor resistance mechanisms positions them as a promising player in the biotech industry.
Keywords: Biotechnology, Cancer, Immunotherapy, R&D, Monoclonal Antibodies, CD112R, PVRIG, Combination Therapy, Preclinical Studies, Innovative Treatment.